• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Rociletinib may be effective in treatment-resistant lung cancer (non-small cell)

byMatthew Growdon
April 30, 2015
in Chronic Disease, Oncology, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In patients with T790M EGFR-mutated treatment-resistant lung cancer who were treated with rociletinib, there was an objective response rate of 59%, compared to only 29% in T790M-negative disease.

2. The most common adverse effect noted in patients treated with rociletinib was hyperglycemia, which was responsive to dose de-escalation and oral hypoglycemic medications.

Evidence Rating Level: 2 (Good)

Study Rundown: A major breakthrough in the treatment of non-small cell lung cancer (NSCLC) was the development of specifically targeted epidermal growth factor receptor (EGFR) inhibitors; however, treatment efforts have been hampered by the emergence of resistance. This is often mediated by a T790M EGFR mutation and occurs commonly with treatment with first-generation EGFR inhibitors.

This drug-company sponsored phase 1-2 study assessed the safety, side-effect profile, and antitumor activity of rociletinib, a small-molecule, orally available mutant-selective inhibitor of EGFR, specifically with the T790M mutation. Patients had EGFR-mutated NSCLC who had previously experienced disease progression while on a first-generation EGFR inhibitor. Patients specifically with the T790M mutation received escalating doses of rociletinib. In this population of 46 patients, the objective response rate was 59% (95% CI, 45 to 73), compared to a rate of 29% (95% CI, 8 to 51) among patients with T790M-negative disease; this dichotomy was seen as a proof-of-concept of the targeted nature of rociletinib. The predominant treatment-related adverse event was hyperglyecmia, which occurred in 22% of patients receiving therapeutic doses of rociletinib; this was managed with dose reduction and oral hypoglycemic agents. Notably, the syndrome of rash, stomatitis, and paronychia commonly associated with inhibition of nonmutant EGFR was absent in this study, underscoring the targeted nature of the treatment.

This study provides encouraging grounding to consider further studies of rociletinib in the treatment of NSCLC associated with the T790M mutation; these studies will be greatly strengthened by larger sample sizes as well as a randomized, controlled study design in order to compare this therapy to existing standard treatments in terms of outcomes as well as side effect profiles.

Click to read the study, published today in NEJM

RELATED REPORTS

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

Fleischner Society Guidelines, 2005 Statement: Limited CT follow-up recommended for small, solitary, pulmonary nodules [Classics Series]

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

Click to read an accompanying editorial in NEJM

Relevant Reading: Epidermal growth factor receptor mutations in lung cancer

In-Depth [prospective cohort]: This phase 1-2 study evaluated the safety and antitumor activity of rociletinib in 130 patients with NSCLC who had disease progression during previous treatment with an earlier generation EGFR inhibitor. Patients underwent tumor biopsy during screening to determine EGFR mutation status. Patients had a median age of 60 years and had most often been treated previously with erlotinib (92%), a first-generation EGFR tyrosine kinase inhibitor. 50% of patients had three or more sites of metastatic disease; 44% had a history of brain metastases. The objective response rate among 46 patients with confirmed T790M mutations was 59% (95% CI, 45 to 73), with a disease control rate of 93%. By comparison, among patients who were T790M-negative, the objective response rate was 29% (95%CI, 8 to 51), with a disease control rate of 59%. Adverse events included hyperglycemia (22%) and grade 1 or 2 diarrhea (20%).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: lung cancer
Previous Post

Doppler velocimetry of fetal middle cerebral artery predicts anemia [Classics Series]

Next Post

Vena cava filters plus anticoagulation do not prevent recurrent pulmonary embolism over anticoagulation alone

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

July 1, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Fleischner Society Guidelines, 2005 Statement: Limited CT follow-up recommended for small, solitary, pulmonary nodules [Classics Series]

June 14, 2022
Surgical site anesthetic infusion may enhance analgesia after mastectomy
Oncology

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

May 30, 2022
#VisualAbstract: Increased physical activity is a long-term protective factor for dementia
StudyGraphics

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 18, 2022
Next Post
Ultrasound-accelerated thrombolysis may improve pulmonary embolism outcomes

Vena cava filters plus anticoagulation do not prevent recurrent pulmonary embolism over anticoagulation alone

Obtaining consent for c-section during labor may be suboptimal

Audit and feedback significantly reduced cesarean delivery rates [QUARISMA trial]

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.